2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Biological activity
Description
Target:
In Vivo
Pramipexole dihydrochloride hydrate (0.25-1 mg/kg; i.p.) significantly reduces the infarction volume in animals[5]. Pramipexole dihydrochloride hydrate improves neurological recovery[5]. Pramipexole dihydrochloride hydrate prevents ischemic cell death via mitochondrial pathways in ischemic stroke[5]. Animal Model: Male Wistar rats weighing 250-300 g (16-18 weeks old)[5] Dosage: 0.25 mg/kg, 1 mg/kg Administration: Intraperitoneal injection, at 1 hour, 6 hours, 12 hours, 18 hours post-occlusion Result: Decreased infarction volume as compared to tMCAO (transient middle cerebral artery occlusion)-only animals.
In Vitro
Pramipexole dihydrochloride hydrate (0.01-10 μM; 72 hours) produces dose-dependent increases of dendritic arborization and soma size[3]. Pramipexole dihydrochloride hydrate attenuates levodopa-induced toxicity in mesencephalic cultures, suggests that pramipexole may be cytoprotective to dopamine neurons in tissue culture[4].
Kinase Assay
Cell Assay
Animal Administration
References
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
